Irinotecán Tarbis

Irinotecan, the active ingredient in Irinotecán Tarbis, is a Topoisomerase I inhibitor presented as a sterile solution for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer in adult patients. GNH USA supplies Irinotecán Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan is used in oncology to target colorectal cancer pathways.

Metastatic colorectal cancer: improves overall survival when combined with standard chemotherapy regimens. Advanced colorectal cancer: reduces tumor progression and may downstage disease. Colorectal cancer (first‑line setting): used as part of combination therapy to enhance response rates.

Irinotecan therapy is associated with a range of adverse reactions.

Common Side Effects: - Diarrhea: often delayed and may be severe. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: generalized tiredness during treatment cycles. - Alopecia: hair loss that may be temporary. - Abdominal pain: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Severe neutropenic infection: febrile neutropenia requiring urgent care. - Acute cholinergic syndrome: sweating, salivation, and bronchospasm. - Severe diarrhea leading to dehydration and electrolyte imbalance. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases.

When using Irinotecán Tarbis, clinicians should observe several safety measures.

Dose adjustment: modify dose in patients with hepatic impairment. Monitoring: perform regular complete blood counts to detect neutropenia. Hydration: ensure adequate fluid intake to mitigate diarrhea‑related dehydration. Drug interactions: avoid concurrent use of strong CYP3A4 inhibitors without dose reduction. Pregnancy and lactation: contraindicated unless benefits outweigh potential fetal risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Irinotecan may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase SN‑38 exposure and toxicity. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy by lowering drug levels. - Anticholinergic agents: may exacerbate cholinergic syndrome.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR due to potential bleeding risk. - Other myelosuppressive agents: increase risk of severe neutropenia. - Proton pump inhibitors: may affect gastric pH and drug absorption.